Memento Medicines launched with a $93 million Series A financing and a licensed lead program aimed at retinal diseases. The company’s start emphasizes ophthalmology as an initial focus area and indicates that it is building a clinical and product development roadmap around a technology- and program-based entry. While deal terms for the licensed asset were not provided in the summary, the combination of a sizable Series A and an already-licensed lead candidate suggests a shorter path to development compared with companies starting entirely from discovery. For investors and partners in retinal therapeutics, the launch adds another funded platform pursuing sight-threatening conditions and may increase competition for later-stage development talent and clinical trial positioning.